Additionally, a study investigating the therapeutic potential of inhibiting EIF4A in AML revealed that primary AML cells exhibit significantly higher levels of EIF4A1 transcripts than other types of cancer. The gene discussed is EIF4A1; the disease is acute myeloid leukemia.